07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

BNC105: Phase II data

Data from 136 evaluable patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase II portion of the open-label, dose-escalation, international Phase I/II DISRUPTOR-1 trial showed that IV BNC105 plus...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

BNC105: Phase I/II data

Data from 15 evaluable patients with partially platinum-sensitive ovarian cancer in first or second relapse in the dose-escalation Phase I portion of an open-label, international Phase I/II trial showed that 12 or 16 mg/m 2...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

BNC105: Additional Phase I/II data

Additional data from 12 patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase I portion of the open-label, dose-escalation, international Phase I/II DisrupTOR-1 trial showed that BNC105 plus Afinitor...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

BNC105: Additional Phase II data

Bionomics said second-line treatment with 16 mg/m 2 IV BNC105 missed the primary endpoint of ORR in a single-arm, open-label, Australian Phase II trial in 30 patients with MPM who progressed after first-line chemotherapy with...
07:00 , Jun 11, 2012 |  BioCentury  |  Finance

Aches for Achillion

Public investors in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lopped $34 million off the HCV company's valuation last week based on two events: the departure of a senior executive and the distribution and sale of some shares...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

BNC105: Phase I/II started

Bionomics began an open-label, international Phase I/II trial to evaluate BNC105 in combination with gemcitabine in about 134 women with partially platinum-sensitive ovarian cancer with 1-2 relapses. The dose-escalation Phase I portion will evaluate 12...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

BNC105: Interim Phase I/II data

Interim data from the Phase I portion of an open-label, dose-escalation, U.S. Phase I/II trial in patients who failed prior tyrosine kinase inhibitor (TKI) therapy showed that 12.6 mg/m 2 BNC105 plus Afinitor everolimus for...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

BNC105: Interim Phase II data

Interim data from a single-arm, Australian Phase II trial in 24 evaluable patients who progressed after first-line chemotherapy with Alimta pemetrexed and cisplatin showed that second-line treatment with 16 mg/m 2 BNC105 was well tolerated....
23:28 , May 13, 2011 |  BC Extra  |  Financial News

Bionomics raises $15.4 million

Bionomics Ltd. (ASX:BNO; OTCBB:BMICY) raised A$14.3 million ($15.4 million) through the sale of 25 million shares at A$0.57 in a private placement to new and existing institutional investors. The price is a 21% discount to...
07:00 , May 9, 2011 |  BC Week In Review  |  Company News

Bionomics cancer, neurology news

Bionomics said it is selling its head office and research facility located in Thebarton to an undisclosed party and has entered a 10-year lease with the purchaser for the location, with the option for two...